

INVESTIGATION ON MMACHC-R161Q PATHOLOGICAL MUTANT FROM *cb1C* DISEASE

Longo L.^{1,2}, Randazzo L.¹, Bollati M.¹, Velazquez Campoy A.³, Carrotta R.¹, Costa M.A.¹, De Rosa M.¹, Ortore M.G.⁴, Mangione M.R.¹, Passantino R.¹, Milani M.¹, Tutone M.², Martorana V.¹, Vilasi S.¹

¹ Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Italy

² Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università di Palermo, Palermo, Italy

³ Institute for Biocomputation and Physics of Complex Systems, University of Zaragoza, Spain

⁴ Dipartimento di Scienze della Vita e dell'Ambiente, Università Politecnica delle Marche, Ancona, Italy

The *cb1C* disease is a rare inborn disorder of the vitamin B12 (cobalamin, Cbl) metabolism characterized by combined methylmalonic aciduria and homocystinuria. The clinical consequences are devastating and, even when early treated with current therapies, the affected children manifest symptoms involving vision, growth, and learning¹. The molecular genetic cause of the disease was found in the mutations of the gene coding for MMACHC, a 282 amino acid protein that transports and processes the various forms of Cbl².

Although the crystal structure of the wild-type protein is available^{3,4}, many molecular features of MMACHC physiopathology remain to be understood and a systematic study on the effect of each specific mutation on the resulting protein is still lacking.

Here we present the biophysical characterization of wild type MMACHC and a variant, p.R161Q, resulting from the most common missense pathological mutation found in *cb1C* patients.

By using a biophysical approach we investigated the stability of the two proteins and their ability to bind and transform the vitamin B12⁵, and to assemble in a dimeric structure. Moreover, interesting indications about the behaviour of the two proteins resulted from the Molecular Dynamics (MD) simulations. Last, we evaluated whether non-specific stabilizers (osmolytes) and drug-like molecules identified by computational methods could restore the functionality in MMACHC mutant.

Overall, our results reveal how a biophysical approach based on the complementarity of computational and experimental methods can offer new insights in the study of the specific effects of the pathological *cb1C* mutation and help prospecting new routes for the *cb1C* treatment.

1. Carrillo-Carrasco et al., *Journal of inherited metabolic disease* 35, 91-102 (2012).

2. Kim et al., *Journal of Biological Chemistry*, 284(48), 33418–33424 . (2009).

3. Koutmos et al., *Journal of Biological Chemistry*, 286(34), 29780–29787 (2011).

4. Froese et al., *Biochemistry*, 51(25), 5083–5090 (2012).

5. Passantino et al., *BBA Proteins and Proteomics* Proteins and Proteomics 1870(2):140793 (2022).